Dianthus Therapeutics (DNTH) Competitors $17.96 -0.67 (-3.60%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$17.96 +0.00 (+0.03%) As of 07/1/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. ARWR, APLS, TWST, VCEL, NAMS, DNLI, KNSA, RXRX, APGE, and CGONShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Twist Bioscience (TWST), Vericel (VCEL), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors Arrowhead Pharmaceuticals Apellis Pharmaceuticals Twist Bioscience Vericel NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Apogee Therapeutics CG Oncology Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability. Is ARWR or DNTH more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,544.23%. Dianthus Therapeutics' return on equity of -29.26% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -45.33% -12.49% Dianthus Therapeutics -1,544.23%-29.26%-27.87% Do analysts rate ARWR or DNTH? Arrowhead Pharmaceuticals currently has a consensus target price of $43.71, indicating a potential upside of 171.69%. Dianthus Therapeutics has a consensus target price of $53.00, indicating a potential upside of 195.10%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do insiders & institutionals have more ownership in ARWR or DNTH? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, ARWR or DNTH? Dianthus Therapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M625.92-$599.49M-$1.40-11.49Dianthus Therapeutics$6.24M92.56-$84.97M-$2.88-6.24 Does the media prefer ARWR or DNTH? In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 3 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 1.14 beat Dianthus Therapeutics' score of 1.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ARWR or DNTH? Arrowhead Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. SummaryDianthus Therapeutics beats Arrowhead Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$599.14M$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-6.2421.1726.2119.74Price / Sales92.56262.85395.44109.12Price / CashN/A41.8936.4957.06Price / Book1.517.237.935.37Net Income-$84.97M-$55.05M$3.15B$248.34M7 Day Performance-2.07%-0.60%0.75%1.67%1 Month Performance2.45%3.77%3.45%4.56%1 Year Performance-31.63%2.20%34.85%18.42% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.6704 of 5 stars$17.96-3.6%$53.00+195.1%-37.8%$599.14M$6.24M-6.2480ARWRArrowhead Pharmaceuticals3.9208 of 5 stars$15.80-1.7%$43.71+176.7%-38.2%$2.22B$3.55M-11.29400Positive NewsAPLSApellis Pharmaceuticals4.515 of 5 stars$17.31-0.7%$40.05+131.4%-50.8%$2.19B$781.37M-9.67770News CoverageTWSTTwist Bioscience4.3388 of 5 stars$36.79+2.4%$50.40+37.0%-24.9%$2.15B$312.97M-11.32990News CoverageVCELVericel2.9104 of 5 stars$42.55+2.0%$61.14+43.7%-7.6%$2.10B$237.22M1,418.81300Positive NewsNAMSNewAmsterdam Pharma2.8964 of 5 stars$18.11-2.5%$42.89+136.8%-11.5%$2.08B$45.56M-9.634DNLIDenali Therapeutics4.5521 of 5 stars$13.99-0.8%$33.71+141.0%-36.6%$2.05B$330.53M-5.24430News CoverageGap UpKNSAKiniksa Pharmaceuticals International3.5593 of 5 stars$27.67-1.3%$38.80+40.2%+51.3%$2.05B$423.24M-110.68220RXRXRecursion Pharmaceuticals1.8775 of 5 stars$5.06+0.6%$7.00+38.3%-31.2%$2.04B$58.84M-2.86400APGEApogee Therapeutics2.7046 of 5 stars$43.43+0.1%$94.60+117.8%+14.7%$2.00BN/A-12.0691High Trading VolumeCGONCG Oncology2.7159 of 5 stars$26.00+0.2%$58.67+125.6%-16.9%$1.98B$1.14M-17.2261 Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Twist Bioscience Alternatives Vericel Alternatives NewAmsterdam Pharma Alternatives Denali Therapeutics Alternatives Kiniksa Pharmaceuticals International Alternatives Recursion Pharmaceuticals Alternatives Apogee Therapeutics Alternatives CG Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
